Biologics in vasculitides: Where do we stand, where do we go from now? - 28/05/15

Doi : 10.1016/j.lpm.2015.04.010

Giulia Pazzola ^{^{1
The first two authors have equally contributed to the manuscript.}}, Francesco Muratore ^{^{1
The first two authors have equally contributed to the manuscript.}}, Nicolò Pipitone, Carlo Salvarani ^⁎
Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera ASMN, department of internal medicine, rheumatology unit, viale Risorgimento, 80, 42123 Reggio Emilia, Italy

^⁎Carlo Salvarani, Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera ASMN, department of internal medicine, rheumatology unit, viale Risorgimento, 80, 42123 Reggio Emilia, Italy.

conectar o crear una cuenta

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

En prensa. Pruebas corregidas por el autor. Disponible en línea desde el Thursday 28 May 2015
This article has been published in an issue click here to access

Summary

Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.

El texto completo de este artículo está disponible en PDF.